This week's biggest % winners & losers : Apr 11 - 15, 22 (wk 15)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: SRRA (54.75 +43.1%), ATRS (5.56 +41.17%), TPTX (33.83 +32.77%), ZIMV (27.5 +16.77%)
• Energy: HPK (30.58 +37.07%), METC (19.43 +22.2%), BTU (32.54 +19.41%), CRK (16.69 +13.61%), EQT (42.5 +10.9%)
• Information Technology: SAIL (19.43 +22.2%), AVNW (34.06 +17.21%)
• Financials: CXW (13.4 +19.96%), LPLA (212.54 +10.39%)
• Consumer Discretionary: FOSL (10.8 +14.16%), BBWI (52.19 +13.14%)

This week's top % losers

• Healthcare: FULC (13.24 -37.75%), NSTG (22.11 -35.14%), ZNTL (26.48 -22.05%), MYOV (11.33 -21.86%), PTGX (19.95 -20.74%), VAXX (3.46 -16.63%), BLFS (16.94 -16.22%), INBX (18.32 -13.3%)
• Consumer Discretionary: RMBL (23.16 -21.2%), RIDE (2.51 -13.45%)
• Information Technology: VLD (5.2 -20.37%), MOMO (4.88 -15.28%), CRDO (11.41 -15.1%), INFY (20.46 -13.67%), CAN (4.19 -11.23%)
• Industrials: AMRC (57.08 -17.61%)
• Consumer Staples: BRFS (3.28 -11.83%)

Antares Pharma (ATRS) to be acquired by Halozyme (HALO) for $5.60 per share

 

Antares Pharma to be acquired by Halozyme (HALO) for $5.60 per share

• Halozyme Therapeutics (HALO) and Antares Pharma (ATRS) announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was unanimously approved by both the Halozyme and Antares Boards of Directors.
• Compelling Financial and Strategic Benefits
  • Immediate Revenue and Non-GAAP Earnings Accretion and Long-Term Financial Upside: The transaction is expected to be immediately accretive to Halozyme's 2022 revenue and non-GAAP earnings, supported by Antares' proprietary product revenues, royalty revenues and profitability. The addition of Antares is also expected to accelerate top- and bottom-line growth and enhance cash flow generation through 2027, increasing Halozyme's flexibility to pursue further growth drivers in the forms of new product and therapy launches, and partnerships.
  • Business Development to Augment Long-Term Growth, Consistent with Strategic Priorities: The addition of Antares' commercial products and existing auto injector capabilities accelerate Halozyme's strategy to drive long-term, durable revenue growth and value creation through focused external growth. Halozyme expects to build on Antares' core platform technology and capabilities to drive incremental, durable revenue opportunities with additional intellectual property protections for Antares technology in place beyond 2030.

=Antares Pharma (ATRS) : XYOSTED regulatory update

Antares Pharma receives official minutes from Type A meeting with FDA regarding XYOSTED NDA 
Based upon this meeting and the FDA minutes, Antares believes that it does not need to conduct any new clinical studies to support the resubmission. The Company anticipates that the resubmission will include re-analyses of existing data, and address labeling and potential post-approval risk mitigation strategies. The Company anticipates submitting the complete response in the second quarter of this year. Under FDA's policies, thirty days after FDA's receipt of the resubmission, the Agency will determine whether the filing constitutes a complete response that addresses all deficiencies in the CRL and, if so, assign a target action date which the Company expects will be within six months of FDA's receipt of the resubmission.

This week's biggest % winners & losers : Oct. 9 - 13, 17 (wk 41)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: ARDX (7.28 +28.76%), AERI (61.7 +17.19%), FPRX (43.36 +11.62%), LCI (23.25 +10.45%)
• Materials: PVG (12.01 +22.93%), RFP (6.4 +20.75%), FBR (16.32 +11.4%), MERC (13.18 +10.25%)
• Consumer Discretionary: CETV (4.8 +10.34%)
• Information Technology: ICHR (32.55 +23.25%), GLUU (4.35 +15.69%), NTNX (26.6 +14.93%), SOHU (64.96 +13.05%), CEVA (47.55 +11.49%), UCTT (33.54 +10.33%), TYPE (22.15 +10.2%)
• Financials: NOAH (40.13 +13.59%)
• Energy: HLX (7.86 +18.55%), SM (19.04 +12.13%), CVRR (11.35 +11.27%)

This week's top 20 % losers

• Healthcare: ATRS (2.33 -40.23%), NSTG (11.08 -31.52%), ONVO (1.55 -24.02%), SGRY (8.95 -20.8%), ARA (12.49 -19%), CYH (5.77 -18.73%), ADMS (19.05 -17.57%), CBPO (79.98 -16.84%), THC (13.15 -15.97%)
• Industrials: HDSN (5.95 -21.61%)
• Consumer Discretionary: ASNA (1.79 -18.26%), FRED (5.41 -17.15%)
• Information Technology: CCRC (12.79 -20.26%), AAOI (47.18 -18.89%), HAWK (34.9 -18.74%), HIMX (9.33 -15.41%)
• Energy: SDRL (0.29 -22.89%), PKD (0.98 -18.48%), CIE (1.05 -17.32%)
• Utilities: PCG (57.72 -16.15%)

Antares Pharma (ATRS) : FDA found deficiencies in the drug Xyosted

Antares Pharma (ATRS) announced Thursday that the U.S. Food and Drug Administration had found deficiencies in the drug Xyosted (testosterone enanthate) during its review process, the company said in a statement. Antares submitted the Xyosted application in December 2016. Antares stock was up 60% this year,

 

Antares Pharma received FDA letter - identified deficiencies as part of their ongoing review of the New Drug Application for XYOSTED

• Co announced that, on October 11, 2017, the Company received a letter from the FDA stating that, as part of their ongoing review of the New Drug Application (NDA) for XYOSTED (testosterone enanthate) injection, they have identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments at this time. The letter does not specify the deficiencies identified by the FDA and there has been no further clarification of the deficiencies by the FDA at this time.
• Anticipates receiving further clarification from the FDA on or before the Prescription Drug User Fee Act (PDUFA) date of October 20, 2017.

This week's biggest % winners & losers : Oct. 2 - 6, 17 (wk 40)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: MNKD (5.04 +132.26%), ELGX (5.74 +28.7%), NTLA (30.88 +24.27%), FLXN (29.72 +22.89%), MYL (38.27 +22%), ICPT (70.12 +20.81%), ATRS (3.89 +20.06%), SGYP (3.47 +19.66%), CFMS (4.13 +17.33%), FMI (46.98 +16.85%)
• Materials: TROX (25.31 +19.95%)
• Industrials: THR (20.83 +15.79%), GOL (24.33 +15.09%), BW (3.81 +14.41%)
• Consumer Discretionary: HOV (2.25 +16.58%), PNK (24.41 +14.55%)
• Information Technology: SNCR (14.19 +52.09%), VNET (7.16 +25.83%)
• Consumer Staples: OME (22.05 +32.43%)
• Telecommunication Services: I (6.54 +39.15%)

This week's top 20 % losers

• Healthcare: MNTA (12.95 -30%), MCRB (11.92 -25.69%), IMMU (11.65 -16.67%), SCMP (10.5 -11.02%)
• Consumer Discretionary: TTS (8.6 -32.28%), ODP (3.95 -13%), ASNA (2.19 -10.82%), GPRO (9.89 -10.17%), HELE (87.45 -9.75%)
• Information Technology: SHOP (97.92 -15.94%), NPTN (4.96 -10.79%), PI (37.12 -10.78%), AAOI (58.2 -10%),
• Financials: NAVI (12.6 -16.11%), MBI (7.65 -12.07%)
• Energy: PDS (2.77 -11.22%), CIE (1.27 -11.19%), HLX (6.63 -10.28%), NE (4.13 -10.22%)
• Consumer Staples: FIZZ (109.23 -11.95%)

Long trade : ATRS +30% (10/17)

• Headquarters: Ewing Township, NJ
• Founded: 1979
• antarespharma.com

a. 21 Sept. #1, 5; vol. 829K
b. 22 Sept:  #1;  vol. 1.0M;  $3

  

Description

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-21.17%	-46.61%
Operating margin	-20.27%	-46.18%
EBITD margin	-	-42.62%
Return on average assets	-15.64%	-32.26%
Return on average equity	-27.89%	-43.36%
Employees	110